PT  - JOURNAL ARTICLE
AU  - El Hadi, Christopher
AU  - Saliba, Rindala
AU  - Maalouly, Georges
AU  - Riachy, Moussa
AU  - Sleilaty, Ghassan
TI  - Machine Learning for COVID-19 Patient Management: Predictive Analytics and Decision Support
AID  - 10.1101/2024.02.26.24303208
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.02.26.24303208
4099  - http://medrxiv.org/content/early/2024/02/28/2024.02.26.24303208.short
4100  - http://medrxiv.org/content/early/2024/02/28/2024.02.26.24303208.full
AB  - Background The global impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has profoundly affected economies and healthcare systems around the world, including Lebanon. While numerous meta-analyses have explored the systemic manifestations of COVID-19, few have linked them to patient history. Our study aims to fill this gap by using cluster analysis to identify distinct clinical patterns among patients, which could aid prognosis and guide tailored treatments.Methods We conducted a retrospective cohort study at Beirut’s largest teaching hospital on 556 patients with SARS-CoV-2. We performed cluster analyses using K-prototypes, KAMILA and LCM algorithms based on 26 variables, including laboratory results, demographics and imaging findings. Silhouette scores, concordance index and signature variables helped determine the optimal number of clusters. Subsequent comparisons and regression analyses assessed survival rates and treatment efficacy according to clusters.Results Our analysis revealed three distinct clusters: “resilient recoverees” with varying disease severity and low mortality rates, “vulnerable veterans” with severe to critical disease and high mortality rates, and “paradoxical patients” with a late presentation but eventual recovery.Conclusions These clusters offer insights for prognosis and treatment selection. Future studies should include vaccination data and various COVID-19 strains for a comprehensive understanding of the disease’s dynamics.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:We, the authors, obtained ethical approval for our study from the Ethics Committee of the Hospital Hotel-Dieu de France (HDF), Beirut, Lebanon, affiliated to the Faculty of Medicine of the Universite Saint Joseph (USJ), Beirut, Lebanon. The Ethics Committee is chaired by Dr. Sami Richa, psychiatrist; Prof. Michel Scheuer, Director of the University Center for Ethics at the USJ secretary; Prof. Georges Abi Tayeh, gynecologist at HDF; Prof. Nasri Antoine Diab, lawyer at the Beirut and Paris Bar Association; Mrs. Soha Abdel Malak, nurse at the HDF - expert in hospital hygiene; Dr. Jad Habib, Family Medicine, at the Centre universitaire de sante familiale et communautaire at USJ; Ms. Hyam Kahi, Social Assistant; Prof. Ronald Moussa, Neurosurgeon at HDF; Dr. May Fakhoury, Chief Pharmacist at HDF; Dr. Lina Iskandar Hawat, Dean's Representative at the Faculty of Religious Sciences at USJ; Mr. Ayad Wakim, Journalist; Ass. Prof. Eliane Nasser Ayoub, Anesthesiology and Resuscitation at HDF. The committee authorized the use of patient data from the Hotel-Dieu de France dataset on condition of anonymity.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authorsASMDAbsolute standardized mean differenceARDSAcute respiratory distress syndromeBICBayesian information criterionCIConfidence intervalCOVID-19Coronavirus disease 2019CRNCreatinineCRPC-reactive proteinCTComputed tomographyCT-PCRCyclic value - polymerase chain reactionHRHazard ratioICUIntensive care unitIL-6Interleukin-6KAMILAK-means of Mixed Large datakNumber of clustersLCMLatent Class ModelsLDHLactate dehydrogenaseOROdds ratioPCTProcalcitoninPMMPredictive mean matchingSARS-CoV-2severe acute respiratory syndrome coronavirus 2VIFVariance inflation factorWHOWorld Health Organization